Prognostic significance of the radiologic features of pneumonitis induced by anti‐PD‐1 therapy

Autor: Rie Kondo, Satoru Miura, Akira Iwashima, Hiroyuki Ishikawa, Aya Otsubo, Masaaki Okajima, Satoshi Shoji, Satoshi Watanabe, Hiroshi Tanaka, Kazuhiro Sato, Kosuke Ichikawa, Tetsuya Abe, Takashi Ishida, Takao Miyabayashi, Hirohisa Yoshizawa, Masachika Hayashi, Koichiro Nozaki, Masaki Terada, Takeshi Ota, Toshiaki Kikuchi
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Male
0301 basic medicine
Cancer Research
Lung Neoplasms
Multivariate analysis
Programmed Cell Death 1 Receptor
NSCLC
immune checkpoint inhibitors
Antineoplastic Agents
Immunological
0302 clinical medicine
Carcinoma
Non-Small-Cell Lung
Original Research
Aged
80 and over
interstitial lung disease
Not Otherwise Specified
Interstitial lung disease
Middle Aged
Prognosis
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Survival Rate
Oncology
030220 oncology & carcinogenesis
Carcinoma
Squamous Cell
Female
Adult
medicine.medical_specialty
Adenocarcinoma of Lung
lcsh:RC254-282
03 medical and health sciences
Internal medicine
medicine
Humans
Radiology
Nuclear Medicine and imaging
Adverse effect
Lung cancer
Aged
Retrospective Studies
Pneumonitis
business.industry
PD‐1
Clinical Cancer Research
Pneumonia
medicine.disease
Discontinuation
030104 developmental biology
Tomography
X-Ray Computed
business
immune‐related adverse event
Follow-Up Studies
Cryptogenic Organizing Pneumonia
Zdroj: Cancer Medicine, Vol 9, Iss 9, Pp 3070-3077 (2020)
Cancer Medicine
ISSN: 2045-7634
Popis: Background Interstitial lung disease (ILD) induced by anti‐programmed‐cell death‐1 (PD‐1) and anti‐PD‐ligand 1 (PD‐L1) is potentially life‐threatening and is a common reason of the discontinuation of therapy. In contrast, an enhancement in antitumor effects was reported in patients who developed immune‐related adverse events, including ILD. Although recent evidence suggests that radiologic patterns of ILD may reflect the severity of ILD and the antitumor immune responses to anti‐PD‐1/PD‐L1 therapies, the association between radiologic features and clinical outcomes remains unclear. Methods Patients with advanced non‐small‐cell lung cancer who were treated with 1st to 3rd line anti‐PD‐1 therapy from January 2016 through October 2017 were identified at multiple institutions belonging to the Niigata Lung Cancer Treatment Group. ILD was diagnosed by the treating physicians, and chest computed tomography scans were independently reviewed to assess the radiologic features of ILD. Results A total of 231 patients who received anti‐PD‐1 therapy were enrolled. Thirty‐one patients (14%) developed ILD. Sixteen patients were classified as having ground glass opacities (GGO), 16 were classified as having cryptogenic organizing pneumonia (COP), and one was classified as having pneumonitis not otherwise specified. Patients with GGO had significantly worse overall survival time compared to patients with COP (7.8 months (95% CI: 2.2‐NE) versus not reached (95% CI: 13.2‐NE); P = 0.0175). Multivariate analysis of all 231 patients also revealed that PS = 1 and ≥2 and GGO were significant predictors of a worse overall survival. Conclusions This study demonstrated that patients who developed GGO exhibited worse outcomes among non‐small‐cell lung cancer patients receiving anti‐PD‐1 therapies.
Interstitial lung disease (ILD) induced by anti‐programmed‐cell death‐1 (PD‐1) is potentially life‐threatening and radiologic patterns of ILD may reflect the severity of ILD and the antitumor immune responses to anti‐PD‐1 therapies. The current study demonstrated that patients who developed ground glass opacities exhibited worse outcomes among non‐small‐cell lung cancer patients treated with anti‐PD‐1 therapies.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje